Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin.

ABSTRACT: Survival and response rates in metastatic colorectal cancer remain poor, despite advances in drug development. There is increasing evidence to suggest that gender-specific differences may contribute to poor clinical outcome. We tested the hypothesis that genomic profiling of metastatic colorectal cancer is dependent on gender.A total of 152 patients with metastatic colorectal cancer who were treated with oxaliplatin and continuous infusion 5-fluorouracil were genotyped for 21 polymorphisms in 13 cancer-related genes by PCR. Classification and regression tree analysis tested for gender-related association of polymorphisms with overall survival, progression-free survival and tumor response.Classification and regression tree analysis of all polymorphisms, age and race resulted in gender-specific predictors of overall survival, progression-free survival and tumor response. Polymorphisms in the following genes were associated with gender-specific clinical outcome: estrogen receptor ?, EGF receptor, xeroderma pigmentosum group D, voltage-gated sodium channel and phospholipase A2.Genetic profiling to predict the clinical outcome of patients with metastatic colorectal cancer may depend on gender.

SUBMITTER: Gordon MA 

PROVIDER: S-EPMC3836679 | biostudies-literature | 2011 Jan

REPOSITORIES: biostudies-literature